General Information of the Drug (ID: M6APDG01583)
Name
Dehydroascorbic acid
Synonyms
dehydroascorbate
    Click to Show/Hide
Status
Investigative
Structure
Formula
C6H6O6
InChI
1S/C6H6O6/c7-1-2(8)5-3(9)4(10)6(11)12-5/h2,5,7-8H,1H2/t2-,5+/m0/s1
InChIKey
SBJKKFFYIZUCET-JLAZNSOCSA-N
PubChem CID
440667
VARIDT Drug ID
DR00260
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Glucose transporter type 1 (SLC2A1)
Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2)
In total 1 mechanisms lead to this potential drug response
Response Summary Glucose transporter type 1 (SLC2A1) is a therapeutic target for Dehydroascorbic acid. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Dehydroascorbic acid through regulating the expression of Glucose transporter type 1 (SLC2A1). [1], [2]
Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3)
In total 1 mechanisms lead to this potential drug response
Response Summary Glucose transporter type 1 (SLC2A1) is a therapeutic target for Dehydroascorbic acid. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Dehydroascorbic acid through regulating the expression of Glucose transporter type 1 (SLC2A1). [1], [2]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
Response Summary Glucose transporter type 1 (SLC2A1) is a therapeutic target for Dehydroascorbic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Dehydroascorbic acid through regulating the expression of Glucose transporter type 1 (SLC2A1). [1], [2]
References
Ref 1 m(6)A-dependent glycolysis enhances colorectal cancer progression. Mol Cancer. 2020 Apr 3;19(1):72. doi: 10.1186/s12943-020-01190-w.
Ref 2 Glucose transporter isoforms GLUT1 and GLUT3 transport dehydroascorbic acid. J Biol Chem. 1997 Jul 25;272(30):18982-9. doi: 10.1074/jbc.272.30.18982.